VIDEO: Richard Stefanacci, DO, Addresses Cost Concerns of Neurodegenerative Diseases
Richard Stefanacci, DO, Associate Professor, Health Policy & Public Health, University of the Sciences, says there are 2 cost concerns associated with neurodegenerative diseases. One is the actual cost of the disease and the second is the cost of diagnostic testing. Dr Stefanacci also says that treatments are now currently inexpensive, but with new emerging therapiess the costs will rise.
This video was taken on Thursday, November 8 at the NAMCP Fall Forum in Las Vegas, NV.
During this segment, experts discuss projects intended to integrate data from oncology trials and describe how these projects will influence the future of drug development and patient care in oncology.
The Institute of Medicine announced yesterday that A. Mark Fendrick, MD, co-editor-in-chief of The American Journal of Managed Care and a national leader in efforts to reform healthcare reimbursement strategies, is among 70 new members elected to the prestigious body.
As accountable care organizations, or ACOs, proliferate across the United States, a question arises for both veteran healthcare leaders and consumers: is the ACO something new, or just a relabeling of managed care vehicles created during the last wave of healthcare reform? A well-run ACO offers something better than the managed care of prior years, according to presenters at the gathering of the ACO and Emerging Healthcare Coalition, which took place October 16-17, 2014, in Miami, Florida.
Attendees at the ACO and Emerging Healthcare Delivery Coalition meeting held October 16-17, 2014, in Miami, Fla., gained insights to help physicians and accountable care organizations achieve the “Triple Aim” of better population health, greater patient satisfaction, and lower costs. This initiative of The American Journal of Managed Care has now attracted more than 120 members.
Myriad Genetics, Inc., announced today that the Medicare Administrative Contractor (MAC) that has jurisdiction over most molecular diagnostic tests has issued its draft notice on how Medicare will provide reimbursement for Prolaris, a test that Myriad has developed to guide treatment decisions in prostate cancer.